简介内容:CJ-2360 is a potent, orally active ALK inhibitor, capable of acting on wild-type ALK (IC50: nM) and F1197M (IC50: nM), G1269A (IC50: nM), L1196M (IC50: nM) and S1206Y ALK mutant (IC50: nM). CJ-2360 strongly inhibited two clinically reported ALK mutants (C1156Y and L1196M) and 468 kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2).